Clinical Research Directory
Browse clinical research sites, groups, and studies.
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Summary
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
Official title: A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone
Key Details
Gender
All
Age Range
15 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
172
Start Date
2022-08-01
Completion Date
2025-12-31
Last Updated
2026-01-09
Healthy Volunteers
No
Interventions
Superselective Adrenal Arterial Embolization
Patients in this group will undergo percutaneous superselective adrenal artery embolization (SAAE). Under fluoroscopic guidance, a microcatheter or an over-the-wire balloon catheter will be navigated into the target adrenal arteries, followed by the slow, controlled infusion of absolute ethanol to achieve localized tissue ablation.
Spironolactone
Patients will be treated with spironolactone.
Locations (3)
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan, China